Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News How EMA’s support for EURneffy 1 mg could disrupt Europe’s pediatric epinephrine market EMA backs EURneffy 1 mg for pediatric anaphylaxis. Find out how ARS Pharmaceuticals and ALK-Abelló could reshape Europe’s allergy care landscape. bySoujanya RaviFebruary 5, 2026